Development of oligodendrocytes, myelin-forming glia in the central nervous system (CNS), proceeds on a protracted schedule. Specification of oligodendrocyte progenitor cells (OPCs) begins early in development, whereas their terminal differentiation occurs at late embryonic and postnatal periods. However, for oligodendrocytes in the cerebellum, the developmental origins and the molecular machinery to control these distinct steps remain unclear. By in vivo fate mapping and immunohistochemical analyses, we obtained evidence that the majority of oligodendrocytes in the cerebellum originate from the Olig2-expressing neuroepithelial domain in the ventral rhombomere 1 (r1), while about 6% of cerebellar oligodendrocytes are produced in the cerebellar ventricular zone. Furthermore, to elucidate the molecular determinants that regulate their development, we analyzed mice in which the transcription factor Sox9 was specifically ablated from the cerebellum, ventral r1 and caudal midbrain by means of the Cre/loxP recombination system. This resulted in a delay in the birth of OPCs and subsequent developmental aberrations in these cells in the Sox9-deficient mice. In addition, we observed altered proliferation of OPCs, resulting in a decrease in oligodendrocyte numbers that accompanied an attenuation of the differentiation and an increased rate of apoptosis. Results from in vitro assays using oligodendrocyte-enriched cultures further supported our observations from in vivo experiments. These data suggest that Sox9 participates in the development of oligodendrocytes in the cerebellum, by regulating the timing of their generation, proliferation, differentiation and survival.
Introduction
The cerebellum, which plays essential roles in a wide range of motor activities, is often used as a model to study neuronal subtype specification because of its highly stereotyped cytoarchitecture (Sillitoe and Joyner, 2007) . For example, the molecular machinery for glutamatergic vs. GABAergic (Hoshino et al., 2005; Machold and Fishell, 2005; Wang et al., 2005) and Purkinje vs. inhibitory interneuron specification (Seto et al., 2014b) has been elucidated. In contrast to the numerous studies on cerebellar neurons, however, development of cerebellar glial cells is poorly understood.
Development of oligodendrocytes has been well studied in the telencephalon and the spinal cord. In those brain regions, most oligodendrocyte progenitor cells (OPCs) are generated in discrete neuroepithelial regions. After leaving the neuroepithelium, OPCs proliferate and migrate towards the final destination. During development, OPCs gradually exit cell cycle, giving rise to oligodendrocytes that subsequently undergo differentiation to become mature myelinated oligodendrocytes.
In the spinal cord, it is known that the development of oligodendrocytes is spatially and temporally regulated by transcription factors under the control of multiple extracellular signaling pathways including canonical Wnt, Sonic hedgehog, Notch and BMPs (Fancy et al., 2009; Nicolay et al., 2007) . In particular, the Sox family of transcription factors regulates the development of oligodendrocytes. Double knockout of Sox9 and Sox10 severely abolishes oligodendrocyte development, although single knockout of Sox9 does not result in gross abnormalities, suggesting that Sox9 and Sox10 are compensatorily involved in oligodendrocytogenesis (Finzsch et al., 2008; Stolt et al., 2003 Stolt et al., , 2002 . In addition, other Sox family proteins, such as Sox5, Sox6, Sox17 and Mechanisms of Development 140 (2016) [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] SoxB1 also participate in oligodendrocyte development (Hoffmann et al., 2014; Sohn et al., 2006; Stolt et al., 2006) .
However, oligodendrocyte development in the cerebellum has been relatively poorly studied. In avians, in ovo transplantation experiments using the chick-quail chimeras have demonstrated that the cerebellar oligodendrocytes are born in the ventral midbrain, followed by migration into the cerebellum (Mecklenburg et al., 2011) . In mice, transplantation studies showed that dissociated cells from the cerebellar primordium did not contain OPCs capable of differentiating into oligodendrocytes, suggesting that cerebellar oligodendrocytes are derived outside of the cerebellum (Grimaldi et al., 2009) . However, neither the exact origins of the cerebellar oligodendrocytes nor the molecular machinery for their development are known.
Recently, Vong et al. reported that genetic ablation of Sox9 in the cerebellum resulted in an increased number of Purkinje cells and GABAergic interneurons, but did not affect astrocytogenesis. As to oligodendrocytogenesis, they only reported that mRNA levels of Olig2 (an oligodendrocyte marker). However, since Olig2 is also expressed in a portion of cerebellar nuclei neurons at this stage, this result does not directly lead to the conclusion that oligodendrocytegenesis is not affected in the mutants. Therefore, the role of Sox9 in the development of cerebellar oligodendrocyte remains elusive.
In this study, we focused on the oligodendrocyte development in the cerebellum. We find that the majority of cerebellar oligodendrocytes are derived from a discrete neuroepithelial region in the ventral r1. In addition, we show that about 6% of cerebellar oligodendrocytes are produced from the cerebellar ventricular zone (VZ). We further reveal that Sox9 plays a pivotal role in the development of cerebellar oligodendrocytes by regulating multiple processes including proliferation and maturation as well as survival. In contrast to the spinal cord, the effects of a lack of Sox9 could not be compensated by Sox10 in the cerebellum. Therefore, this work provides insights into the origins and developmental machinery for cerebellar oligodendrocytes.
Materials and methods

Animals
All animal experiments in this study have been approved by the Animal Care and Use Committee of the National Institute of Neuroscience, National Center of Neurology and Psychiatry (Tokyo, Japan; project 2008005) . The En1 Cre , Ptf1a
Cre , Tg-Atoh1-Cre, Rosa26-EYFP and Sox9 flox mouse lines have been described previously (Akiyama et al., 2002; Fujiyama et al., 2009; Hoshino et al., 2005; Kimmel et al., 2000; Srinivas et al., 2001 ).
Antibodies and immunohistochemistry
Embryos were fixed with 4% paraformaldehyde (PFA) in PBS and cryoprotected with 30% sucrose in PBS. After the embryos were embedded in OCT compound, 14 μm cryosections were made. Sections were incubated in blocking buffer containing 1% BSA and 0.1% Triton X-100 in PBS at room temperature (RT) for 1 h and subsequently immunolabeled using the following primary antibodies in blocking buffer at 4°C overnight: anti-HuC/D (1:500; mouse; Invitrogen), bromodeoxyuridine (BrdU) (1:200; sheep; Abcam), cleaved Caspase-3 (1:100; rabbit; Cell Signaling Technology), Pax6 (1:500; rabbit; Covance), Pax2 (1:200; rabbit; Invitrogen), Corl2 (1:500; rabbit; a kind gift from Dr. Y. Ono, KAN Research Institute, Kobe, Japan), GFP (1:50; rat; a kind gift from Dr. A. Imura, Foundation for Biomedical Research and Innovation, Kobe, Japan), GFP (1:2000; rabbit; Invitrogen), Ki67 (1:500; rat; eBioscience), Lhx1/5 (1:3000; mouse; DSHB), Olig2 (1:500; goat; R&D Systems), Olig2 (1:500; rabbit; Millipore), GFAP (1:1; rabbit; Dakocytomation), Calbindin (1:500; rabbit; Chemicon), myelin basic protein (1:500; MBP; mouse; Millipore), NG2 (1:250; rabbit; Millipore), Sox9 (1:500; goat; R&D Systems), PDGFRα (1:200; rat; BD Biosciences), Sox10 (1:200; goat; Santa Cruz), Islet (1:2; mouse; Developmental Studies Hybridoma Bank; 39.4D5), Ascl1 (1:250; mouse; BD), Ngn2 (1:250; goat; Santa Cruz), HNF-3β (1:250; goat; Santa Cruz), Ptf1a (1:250, rabbit) (Yamada et al., 2014) and Atoh1 (1:1000, rabbit) (Yamada et al., 2014) , Lmx1a (1:200; hamster; a kind gift from Dr. Y. Ono, KAN Research Institute, Kobe, Japan) (Ono et al., 2007) . Specimens were subsequently rinsed with PBS and incubated with secondary antibodies conjugated with Alexa Fluor 488, Alexa Fluor 568, Alexa Fluor 594, or Alexa Fluor 647 (1:400; Invitrogen) or DAPI (1:5000; Invitrogen) in blocking buffer containing 1% BSA and 0.2% Triton X-100 in PBS at RT for 2 h. Fluorescence images were acquired using a Zeiss LSM 780 confocal microscopy system (Carl Zeiss, Oberkochen, Germany) and ZEN 2009 software or KEYENCE All-in-One fluorescence microscope (BZ-X700, KEYENCE).
BrdU incorporation experiment
Timed pregnant mice were given intraperitoneal injections of BrdU at 100 mg/kg. 24 h after the BrdU injection, embryos were harvested, fixed and subjected to immunohistochemical analyses as follows. After immunolabeling with the primary antibodies, tissue sections were post-fixed with 4% PFA at RT for 20 min and treated with 2 N hydrochloric acid at 37°C for 30 min. The sections were rinsed in PBS, and incubated with anti-BrdU antibody overnight. The cell-cycle exit rate was calculated as the number of BrdU and Olig2-double-positive cells that remain in the cell cycle and was shown as a percentage of the total BrdU, Olig2, Ki67-triple-positive cells.
Cell culture
For mouse primary oligodendrocyte-enriched cell cultures, ventral r1 or cerebellar precursors were isolated from E12.5 embryos and neurospheres were generated as described previously (Pedraza et al., 2008) . Neurospheres were then dissociated and cultured in growth media containing N 2 supplement (Invitrogen), 10 ng/ml bFGF (peprotech) and 10 ng/ml PDGF-AA (peprotech) for 10 days to enrich for Olig2-positive OPCs (oligospheres). For electroporation, the cells passaged by trypsinization were subjected to five electric pulses at 125 V with 2.5 ms duration and 50 ms intervals using the NEPA21 electroporation system (Nepa Gene). Cells were then cultured in oligodendrocyte proliferation media with N2 supplement, 10 ng/ml bFGF and 10 ng/ml PDGF-AA, or oligodendrocyte differentiation media containing N2 supplement, 15 nM T3 (Sigma) and 10 ng/ml CNTF (peprotech) to promote oligodendrocyte differentiation. For immunocytochemistry, cells were fixed with 4% PFA, permeabilized with PBS + 0.5% Triton X-100, and stained with primary antibodies diluted in 10% goat serum in PBS.
Electron microscopy
Mouse embryos were fixed by immersion with 2% paraformaldehyde (PFA)/2% glutaraldehyde (GLA) in 0.1 M sodium phosphate buffer (PB), and sagittal sections (200 μm in thickness) were prepared by a microslicer (VT1000S; Leica). The sections were treated with 1% osmium tetroxide in 0.1 M cacodylate buffer, pH 7.2, for 60 min, followed by washing with distilled water for 60 min, stained with 3% uranyl acetate for 60 min, dehydrated, and embedded in Epon812 (TAAB). After polymerization of the resin, each tissue sample was cut into ultrathin sections by a diamond knife on an ultramicrotome (Leica EM UC6; Leica). The ultrathin sections were mounted on single-slot grids coated with polyvinyl formal membrane. The ultrathin sections examined by electron microscopy (TecnaiSpiritBT; FEI) at 120 kV.
Results
The origin of cerebellar oligodendrocytes in mice
To examine which brain regions cerebellar oligodendrocytes originate from in mice, we performed in vivo fate-mapping analysis using a Cre/LoxP recombination-based lineage tracing technique. Rosa26-EYFP (REY) reporter mice were crossed with three different Cre driver lines to obtain offspring in which progenies of Creexpressing cells were labeled with EYFP. The cerebellar primordia of those embryos were co-immunolabeled with EYFP (detected by anti-GFP antibody) and PDGFRα, a specific marker for OPCs (Fig. 1A-I) .
At the mid-embryonic stages (E9.5~), En1 is expressed in the caudal midbrain and r1 (the En1-area) (Sgaier et al., 2007 (Sgaier et al., , 2005 . Therefore, all the cells derived from the En1-area are labeled in the En1 cre/+ ;REY mice. Immunostaining at E18.5 showed that all PDGFRα-expressing cells were EYFP-positive in the En1 cre/+ ;REY cerebella ( Fig. 1A-C, J) . This suggests that the origins of the cerebellar oligodendrocytes reside exclusively within the En1-area. In the cerebellar primordium of Ptf1a cre/+ ;REY embryos, cells derived from the Ptf1a-expressing VZ are labeled with EYFP (Hoshino et al., 2005) . In those cerebella at E18.5, 6.0 ± 2.2% of PDGFRα + cells expressed EYFP (Fig. 1D-F, J) . In addition to the cerebellum, Ptf1a is also expressed in the VZ of more caudal parts of the brain stem (Fujiyama et al., 2009; Yamada et al., 2007) . However, if the oligodendrocyte origins are limited to the En1-area (Fig. 1A -C, J), this result suggests that about 6% of cerebellar oligodendrocytes emerge from the cerebellar VZ. In contrast, no PDGFRα + cells were labeled with EYFP in Tg-Atoh1-Cre;REY cerebella in which cells originating from the Atoh1-expressing RL are labeled ( Fig. 1G -I, J) (Fujiyama et al., 2009) , indicating that the RL does not produce cerebellar oligodendrocytes. These findings suggest that about 6% of cerebellar oligodendrocytes are produced from the cerebellar VZ while the rest are derived from extracerebellar regions within the En1-area. In addition to the cerebellum, we also investigated oligodendrocytes in other regions within the En1-area using the same E18.5 samples. These findings suggest that the majority of oligodendrocytes in the ventro-caudal midbrain and ventral r1 are generated within the non-cerebellar En1-area while a small population of oligodendrocytes is derived from outside the En1-area. It has been reported that the oligodendrocytes in the ventral spinal cord and telencephalon are generated from the Olig2-expressing neuroepithelium. After leaving the neuroepithelium, they migrate into the mantle zone and start to express PDGFRα (Lu et al., 2002; Takebayashi et al., 2002; Zhou and Anderson, 2002) . We confirmed by immunohistochemistry that all PDGFRα-positive cerebellar oligodendrocytes co-express Olig2 (n = 3 embryos, data not shown). This implies that the origins of cerebellar oligodendrocytes in the En1-area are also Olig2-expressing neuroepithelium. Given this speculation, we searched for Olig2-expressing neuroepithelial regions within the En1-area. After performing extensive immunolabeling with Olig2 at mid-embryonic stages, we found two Olig2-expressing neuroepithelial regions within the En1-area ( Fig. 2A-D) . One is within the cerebellar ventricular zone (white arrowheads in Fig. 2C , D) from which Purkinje cells are generated, as was previously reported (Seto et al., 2014b) . The other is in a limited portion of the neuroepithelium in the ventral r1 (the Olig2 NE domain, yellow arrowheads in Fig. 2A, B) . By double immunostaining with Olig2 and Lmx1a, a marker for ventral midbrain (Andersson et al., 2006) , we confirmed that the ventral Olig2 signal in Fig. 2B is not in the midbrain but in the r1. We could not detect any other Olig2 expression in the neuroepithelium within the En1-area. These findings raised the possibility that the Olig2 NE domain in the ventral r1 give rise to the majority (~94%) of the cerebellar oligodendrocytes. This further implies that all of oligodendrocytes in the dorsocaudal midbrain and the majority of oligodendrocytes in the ventrocaudal midbrain and ventral r1 are also derived from the Olig2 NE domain (Fig. 2L) .
To test this possibility, we performed immunostaining with Olig2 and PDGFRα on coronal sections of the ventral r1 at E11.5 ( Fig. 2E-H ). PDGFRα and Olig2 double-positive cells were found in the mantle zone only in the vicinity of the Olig2 NE domain (white arrows in Fig. 2F -H), although PDGFRα expression was not observed in the neuroepithelium (yellow arrow in Fig. 2E ). These findings suggest that cells in the oligodendrocyte lineage are generated from the Olig2 NE domain in the ventral r1.
To investigate when and how the ventral r1-derived oligodendrocytes migrate into the cerebellum, we examined PDGFRα + cells to detect oligodendrocyte lineage cells in the cerebellum at different developmental stages. Although there was little PDGFRα immunoreactivity at E14.5 ( Fig. 2I ), the PDGFRα + cells began to appear in the cerebellum at E16.5 and increased in number at E18.5 (Fig. 2J, K) . This implies that it takes approximately 5 days for oligodendrocyte lineage cells to migrate from the Olig2 NE domain into the cerebellum.
Sox9 expression in ventral r1 and cerebellum during development
To investigate the molecular machinery for the development of cerebellar oligodendrocytes, we focused on Sox9. Sox9 is a transcription factor with multiple roles in the development of various organs including testis, chondrocytes, pancreas, intestine, kidney, heart valves and derivatives of the neural crest (Akiyama, 2008; Chaboissier et al., 2004; Furuyama et al., 2011; Kamachi and Kondoh, 2013; Lefebvre et al., 2007; Seymour et al., 2007) . Sox9 has been implicated in the initiation and maintenance of the neural stem cell populations in embryonic and adult CNS (Cheng et al., 2009; Scott et al., 2010) . In the spinal cord, the genetic deletion of the Sox9 gene in mice results in an extended period of neurogenesis, coupled with a delay in the onset of oligodendrocyte production, suggesting the role of Sox9 as a developmental switch from neurogenesis to gliogenesis (Stolt et al., 2003) . In the cerebellum, while Sox9 is required for proper production of inhibitory neurons, its role in oligodendrocyte development has not been investigated (Vong et al., 2015) . Therefore, we postulated that Sox9 could play an important role in the generation and differentiation of cerebellar oligodendrocytes.
Consistent with previous reports, our immunohistochemical analyses on the developing mouse revealed that Sox9 is present along the entire neuroepithelium of ventral r1 at E11.5 as well as the cerebellar primordium at E13.5 (Fig. 3A , I Vong et al., 2015) . At later stages, however, immunoreactivity to Sox9 was detected not only in the proliferative zones, but also in the parenchymal cells in both regions ( Fig. 3B -D, J, K). At E18.5, the width of the Sox9-expressing region in the neuroepithelia was decreased, coupled with reduction of neuroepithelial cells whereas the Sox9 + cells in the parenchyma were dramatically increased (Fig. 3D, K) . Next, we performed co-immunostaining with Sox9 and several developmental markers for the oligodendrocyte lineage ( Fig. 2E-H,  Fig. 3E -H, L-S). In the ventral r1 at E11.5, Sox9 was expressed throughout the neuroepithelium, including the Olig2 NE domain (Fig. 3E) . In addition, Sox9 expression was also found in Olig2-and PDGFRα-double positive cells (OPCs) in the mantle zone in the vicinity of the Olig2 NE domain at E11.5 ( Fig. 3E-H) . The Sox9 expression in the oligodendrocyte lineage is maintained at E12.5 and E14.5 in the ventral r1 as indicated by co-labeling with PDGFRα, Olig2, NG2 and Sox10 (Fig. 3L , M, data not shown). In the cerebellum, Sox9 expression is still found in PDGFRα-positive cells in E16.5 and E18.5 cerebella (Fig. 3P, Q) , while it is undetectable in mature oligodendrocytes in the postnatal ventral r1 and cerebellum (Fig. 3N , O, R, S). These findings indicate that Sox9 is expressed in OPCs/oligodendrocytes of the cerebellum throughout developmental stages but not in the adults.
Impairment of oligodendrocyte development in Sox9 mutant cerebellum
To genetically investigate the role of Sox9 in the cerebellum during development, the Sox9 gene was conditionally ablated using the Cre/LoxP recombination strategy, because even heterozygous loss of the Sox9 gene body-wide caused embryonic lethality at E11.5 (Akiyama et al., 2002) . Mice with a Sox9 flox allele (Akiyama et al., 2002) were crossed with En1 cre -carrying mice to specifically knock out the Sox9 gene in the En1-area of their offspring. We confirmed by immunohistochemistry that the Sox9 protein was completely eliminated in the ventral r1 (at E11.5) and the cerebellum (at E18.5) in the Sox9 homozygous (Sox9 flox/flox ; En1 Cre ) mutants without affecting its expression in other brain regions (Fig. 4A, B , data not shown). As the homozygotes die just after birth, we examined their brains at embryonic stages.
We did not find any gross morphological differences between the control and Sox9 mutant brains (data not shown). In E18.5 cerebella, we examined the expression of various cell type specific markers such as Pax2 (GABAergic interneurons, Fig. 4C, D) , Pax6 (granule cells, Fig. 4E, F) , calbindin (Purkinje cells, Fig. 4G , H) and BLBP (radial glia and astrocytic cells, Fig. 4I, J) . However, no changes were observed in the expression of these markers in the mutants, indicating that Sox9 is not indispensable for the development of cerebellar neurons and astrocytic cells.
In contrast, we detected abnormal expression profiles in markers for the oligodendrocyte lineage in the mutant cerebella. At E14.5, PDGFRα was not detectable in the cerebellum of both control and Sox9 mutant embryos (Fig. 5G , data not shown). As was also observed in the wild type cerebella (Fig. 2K) , this may reflect the fact that OPCs generated from the Olig2 NE domain in the ventral r1 have not reached the cerebellar primordia by this stage. In the homozygous cerebella, there were fewer PDGFRα-positive cells at E16.5 and even less at E18.5 compared to wild type (Fig. 5A, C, D, F, G) . Interestingly, in heterozygous mutant cerebella, the number of PDGFRα-positive cells appeared to increase at E16.5 but then decrease at E18.5 (Fig. 5B, E, G) . These observations suggest that the number of OPCs transiently increase (at E16.5) and then decrease (at E18.5) in heterozygotes, while they are significantly decreased at E16.5 and almost absent at E18.5 in homozygotes. These observations were further confirmed using another oligodendrocyte lineage marker, Sox10 (Fig. 5H) .
In the cerebellum, Olig2 is known to be expressed in some cerebellar nuclei (CN) neurons (Seto et al., 2014a) in addition to OPCs/oligodendrocytes. NG2 is expressed in OPCs and vascular pericytes (Zhu et al., 2008) . Thus double staining with Olig2 and NG2 allowed us to identify cells in the oligodendrocyte lineage, and confirmed our observations regarding OPC numbers in the Sox9 mutants (Fig. 5I) . In contrast, the numbers of Olig2-positive CN neurons (Olig2
were not affected in homozygous mutant cerebellum (Fig. 4K, L) . We also investigated the morphology of oligodendrocytes by staining with NG2 and Olig2, as NG2 allows us to visualize the entire cell morphology (Nishiyama et al., 2009) . The processes of oligodendrocytes were short and poorly arborized in the cerebella of the Sox9 mutant embryos in a gene dosage dependent manner (Fig. 5J-O) . Furthermore, we examined the ultrastructure of myelin by transmission electron microscopy (Fig. 5P) . In the control cerebellum at E18.5, formation of numerous myelin sheets surrounding the axons could be observed (left panel in Fig. 5P ). In contrast, the number of myelin sheets in the Sox9-deficient mice was significantly reduced in a gene dose dependent manner (Fig. 5P, Q) . We next investigated apoptosis using an active Caspase3 (Fernandes-Alnemri et al., 1994; Ura et al., 2001 ). In the homozygous cerebella, apoptotic cells were significantly increased at both E16.5 and E18.5 (Fig. 5R, S) . These findings suggest that Sox9 is involved in cerebellar oligodendrocyte development, particularly in the regulation of their number, morphology and survival.
Abnormalities in oligodendrocyte development in the ventral r1 in En1
Cre/+ ;Sox9 flox mice
Next, in the Sox9 mutant mice, we investigated oligodendrocyte development in the ventral r1 at their origin in the Olig2 NE domain. Consistent with our observations in wild type mice ( Fig. 2A-D, E) , Olig2 expression appeared in a discrete region facing the ventricle (the Olig2 NE domain) at E11.5 in the control embryos (Fig. 6A) . However, Olig2-expressing cells at the corresponding region were dramatically decreased in the heterozygous mutants, and almost completely absent in homozygous mutants at the same embryonic stage (Fig. 6B, C, P) . At E12.5, Olig2-expressing cells in this region increased in heterozygotes to a similar extent as the control animals ( Fig. 6D, E, P) . However, in the homozygotes, Olig2 expression was not detectable in the corresponding region at E12.5 ( Fig. 6F, P) . These findings suggest that the onset of Olig2 expression in the neuroepithelium of the ventral r1 (i.e. the Olig2 NE domain) is delayed in the Sox9 mutants in a gene dosage-dependent manner.
In the control mice at E12.5, some oligodendrocyte lineage (PDGFRα + ) cells appeared at the mantle zone adjacent to the Olig2 NE domain (Fig. 6D) . These cells gradually increased as development proceeded and plateaued at E16.5 in the control mice (Fig. 6G , J, M, Q). However, in the homozygous mutants, PDGFRα + cells were not detectable in the mantle zone at E12.5 (Fig. 6F) , appearing only at E14.5 and in much fewer numbers compared to control (Fig. 6I , L, O, Q). Interestingly, in the heterozygous mutants, the number of PDGFRα + cells was higher at early stages (E12.5 and E14.5) than in control (Fig. 6E, H, Q) . This trend was also confirmed by immunostaining with other markers for the oligodendrocyte lineage, Olig2 and Sox10 (Fig. 6R, S) , all of which suggest that the number of cells in the oligodendrocyte lineage is decreased in the homozygotes, and transiently increased in heterozygotes, mimicking the phenotype in the cerebellum. Next, we examined the cell cycle remaining/exit ratios of oligodendrocyte lineage cells in the developing ventral r1. Brain sections of four different embryonic stages between E12.5 to E18.5 were prepared 24 h after pulse-labeling with BrdU, and co-stained with Ki67 and Olig2 (Fig. 7G) . The number of oligodendrocyte lineage cells that remained in a proliferative state 24 h after BrdU incorporation was estimated by counting BrdU + Ki67 + Olig2 + cells in the mantle layer. In this experimental condition, the ratio of cells remaining in the cell cycle was 57.1 ± 5.0% at E12.5 in the control animals, but increased to 65.3 ± 8.6% in the heterozygous embryos at E12.5 (Fig. 7G ). In the mantle layer of the homozygous animals at the same stage, no oligodendrocyte lineage cells were found, thus we could not obtain a ratio (Fig. 7G) . However, the cell cycle remaining ratios at later stages were similar in heterozygotes and homozygotes compared to the control animals, except for an abnormally increased ratio in homozygous embryos at E18.5 (Fig. 7G) .
Probably reflecting the increased cell cycle remaining ratio in the heterozygotes at E12.5, the absolute number of proliferative as well as ration of proliferative oligodendrocyte lineage cells was increased at E12.5 and E14.5 in heterozygous animals (Fig. 7B, H, I ). On the other hand, the absolute number of proliferative oligodendrocyte lineage cells was relatively decreased in homozygotes at E14.5 (Fig. 7H) , probably because of the delay in oligodendrocytogenesis (Fig. 6C, F, P) . These findings suggest that two functional copies of Sox9 are required to elicit proper cell cycle exit at early stages of oligodendrocytogenesis (E12.5) and loss of one copy results in partial impairment of the cell cycle exit. However, this role can be compensated for at later stages. We suspect that upregulation of the cell cycle remaining ratio of OPCs in the ventral r1 of heterozygotes at early stages (e.g. E12.5) causes a transient increase of oligodendrocyte lineage cells at later stages not only in the ventral r1 (E12.5, E14.5, Fig. 6E , H, Q-S) but also in other regions that receive oligodendrocytes from the Olig2 NE domain, such as the cerebellum (E16.5, Fig. 5B, G-I ).
In addition, we found that apoptotic cells (active caspase3 + cells)
were increased in the mantle zone of homozygotes at E14.5, E16.5 and E18.5, but not in heterozygotes (Fig. 7J ). This suggests that at least one copy of Sox9 is necessary for cells to survive and loss of both copies results in apoptosis. In addition to delayed production of OPCs, this may partly account for the reduced number of oligodendrocyte lineage cells in homozygotes (Fig. 6Q-S) .
In the homozygous animals (Sox9 flox/flox ; En1
Cre/+ ), Sox9 expression was undetectable at E14.5 in the ventral r1 (Fig.8A) , and the cerebellum (data not shown). However, we observed increasing numbers of Sox9-expressing cells during late embryogenesis (E16.5, E18.5, Fig. 8A ) in the ventral r1, whereas such cells were not observed at the same stages in the cerebellum (data not shown). These Sox9-expressing cells are thought to come from outside the En1-area in the homozygous embryos. The ratio of Sox9-expressing cells in Olig2-positive cells in the ventral r1 of the homozygotes were 63.6 ± 17.7% and 80.2 ± 10.9% at E16.5 and E18.5, respectively (Fig. 8B ). This suggests that the majority of oligodendrocyte lineage cells in that brain region are derived from outside the En1-area in homozygotes, compared to only about 14% of oligodendrocytes were from outside that area in controls (Fig. 1L) . Co-immunostaining with Olig2 and Ki67 showed that oligodendrocytelineage cells from the extra-En1-area (Sox9 + ) of the homozygotes are more proliferative (32.2 ± 10.7%) than those in controls (19.5 ± 5.1%), while those from the Olig2 NE domain (Sox9 − ) of the homozygotes are much less proliferative (7.6 ± 4.0%) than control (Fig. 8C, D) . We suspect that, in homozygotes, those "immigrants" may try to compensate for the loss of oligodendrocytes from the Olig2 NE domain by increasing their proliferative ratio. This could explain the increased proliferation indices in the total oligodendrocyte lineage cells in the ventral r1 of the E18.5 homozygotes (Fig. 7F, G-I) .
Deletion of Sox9 impairs oligodendrocyte development in vitro
In order to investigate the phenotypes of Sox9 mutant oligodendrocytes in vitro, we utilized an oligodendrocyte culture system (Chen et al., 2007; Pedraza et al., 2008) . While it is easy to dissect out the cerebellum from embryos, it is relatively difficult to dissect out the ventral r1. So we used the brain fragment that contains caudal midbrain and ventral r1 (Vr1-Cmb), which easily discriminated. We first generated neurospheres from dissociated Vr1-Cmb from Sox9
flox/+ and Sox9 flox/flox animals at E12.5. These neurospheres were again dissociated and cultured in growth media to form oligospheres enriched in OPCs. Because the Olig2 NE domain was the only neuroepithelial region that expresses Olig2 within Vr1-Cmb, it can be deduced that all or, at least, the majority of OPCs are generated from Olig2 NE domain using this culture assay. Subsequently, the oligospheres were dissociated and electroporated with Cre recombinase-and GFP-vectors to ablate the Sox9 gene at the flox locus. These cells were immediately cultured either in proliferation or differentiation media where cells could remain as OPCs or could elicit oligodendrocyte maturation, respectively. In this assay, Olig2 can be used as a specific marker for cells in the oligodendrocyte lineage.
In the proliferation media at 3 and 7 days in vitro (DIV3 and DIV7), the number of Olig2-expressing cells derived from the Vr1-Cmb was increased in heterozygous and decreased in homozygous samples, compared with the control (Fig. 9A, B, D) . In the same conditions, the ratios of proliferating cells (Ki67 + ) in the oligodendrocyte lineage were increased in heterozygotes (Fig. 9A, C, E) . In contrast, the homozygous mutant OPCs exhibited a normal proliferative ability however had a dramatic increase in apoptotic cells at DIV3 (Fig. 9C, E, F) . These findings suggest that OPCs from the Vr1-Cmb (presumably from the ventral r1) are more proliferative in heterozygotes and more apoptotic in homozygotes than controls, which mimic the in vivo phenotypes at mid-embryonic stages, confirming that two copies of Sox9 are required to elicit normal proliferation and one copy of Sox9 is necessary for cells to survive. In the differentiation media at DIV3 and DIV7, control cells differentiated as culturing proceeded, exhibiting strong expression of MBP (a marker for mature oligodendrocytes) and complex arborized processes (Fig. 10A) . However, heterozygous and homozygous Sox9-deficient oligodendrocytes expressed less MBP and exhibited poor process formation (Fig. 10A, B, D) . In homozygotes, there were fewer oligodendrocyte lineage cells and those that were present were more apoptotic than in control (Fig. 10C, E, F) . These phenotypes mimicked those observed in vivo, and further support that two copies of Sox9 are required for proper differentiation of oligodendrocytes derived from the Olig2 NE domain in the ventral r1 and at least one copy is necessary to avoid cell death. In addition, these in vitro experiments suggest these roles occur cell-autonomously.
We performed similar experiments on cells derived from the E12.5 cerebellum. Oligodendrocyte lineage cells were observed in both the proliferation and differentiation media (Fig. 11A, B, C) , but far fewer compared to the Vr1-Cmb cultures (Fig. 11E) . We suspect that those cells are derived from the cerebellar VZ where a portion (~6%) of cerebellar oligodendrocytes emerges (Fig. 1J ). In the proliferation media, cells in the oligodendrocyte lineage were increased in heterozygotes and decreased in homozygotes (Fig. 11B ). In the differentiation media, cells from mutant cerebella exhibited poor morphology and lower MBP expression in a gene dosage-dependent manner (Fig. 11A,  D) . In homozygotes, the number of those cells was reduced (Fig.11C ). These findings suggest that cerebellum-derived OPCs/oligodendrocytes have characteristics similar to those derived from Vr1-Cmb.
Discussion
It was originally thought that, in the spinal cord and the telencephalon, oligodendrocyte lineage cells or OPCs exclusively arise from restricted regions of the ventral ventricular neuroepithelium (Rowitch, 2004) . For example, the oligodendrocytes in the spinal cord originate from pMN domain in the ventral VZ of the spinal cord (Rowitch, 2004) . Subsequent studies by several groups revealed that the second wave of oligodendrocyte generation at the dorsal spinal cord occurs in the later embryonic stages (Cai et al., 2005; Fogarty et al., 2005; Vallstedt et al., 2005) . Moreover, in forebrain, the oligodendrocytes are supplied from spatially and temporally distinct neuroepithelial regions including the medial and lateral ganglionic eminence in the embryonic stages and the dorsal forebrain after birth . Despite these studies, the detailed origin of oligodendrocytes is still obscure since exploration of the cerebellum and the metencephalic vesicle remain incomplete. In avians, an extracerebellar source of cerebellar oligodendrocytes has been recently identified by chick-quail chimera experiments (Mecklenburg et al., 2011) . Mecklenburg et al. revealed that most cerebellar oligodendrocytes, plus a small contingent of astrocytes, are derived from the parabasal bands of the mesencephalic neuroepithelium. In mammals, transplantation and electroporation experiments have provided circumstantial evidence indicating that most (if not all) of the cerebellar oligodendrocytes are derived from extracerebellar locations (Grimaldi et al., 2009) . However, the origins of mammalian cerebellar oligodendrocytes remained unclear. Furthermore, the origins of oligodendrocytes in the midbrain and the ventral r1 region are not known in any vertebrates. This study aimed to fill this gap.
By genetic lineage tracing analyses, we revealed that around 6% of cerebellar oligodendrocytes are generated from the VZ of the cerebellar primordium. We also showed that the remaining cerebellar oligodendrocytes are all derived from the extracerebellar brain regions within the En1-area. It may be, however, possible that the oligodendrocytes generated in these regions of the postnatal and adult brains are derived from the distinct germinal zones, which is likely as observed in the forebrain .
It has been reported that most oligodendrocytes in the spinal cord and the telencephalon are generated from the Olig2-expressing neuroepithelial domain at the mid-embryonic stages (Lu et al., 2002; Takebayashi et al., 2002; Zhou and Anderson, 2002) . We observed that there was only one Olig2 expression region in the neuroepithelium (Olig2 NE domain) of the extracerebellar En1-area. The Olig2 NE domain is found in a discrete neuroepithelial region in the ventral r1 at E11.5. At slightly later stages, we observed cells in the oligodendrocyte lineage that appeared in the mantle zone in the vicinity of the Olig2 NE domain and then migrated away from this region. These findings strongly suggest that the extracerebellar origin of cerebellar oligodendrocytes corresponds to the Olig2 NE domain in the ventral r1, although we cannot exclude the possibility that a small portion may be generated from an Olig2-nonexpressing region, as observed in the forebrain ( Kessaris et al., 2006) . Moreover, in in vitro assays, the ability of the cerebellar primordium to produce oligodendrocytes was observed to be lower than that of Vr1-Cmb. This result is consistent with the fact that far fewer oligodendrocytes are produced from the cerebellar VZ in vivo.
We also clarified that Sox9 is essential for oligodendrocyte development in the En1-area. In the cerebellum of homozygous En1-Sox9-deficient mice (En1-Cre:Sox9 flox/flox ), the number of oligodendrocytes was significantly reduced and the residual oligodendrocytes appeared quite premature. In the early embryonic stages (E11.5 and 12.5) of the Sox9 homozygote mutant mice Olig2-positive OPCs are absent in the neuroepithelium of ventral r1 (Fig.6C, F) . Therefore, the residual cerebellar oligodendrocytes in the Sox9 cKO mice at E16.5 are probably derived from the cerebellar VZ. The ablation of Sox9, however, results in the subsequent loss of these cells at E18.5 due to defects in the progress of oligodendrocyte development.
In contrast, more oligodendrocytes were observed in the ventrocaudal midbrain and ventral r1 of En1-Cre:Sox9 flox/flox animals at E18.5.
However, about 80% of the oligodendrocytes expressed Sox9, indicating that those cells were derived from outside En1-area where Sox9 gene was not deleted. This is consistent with our observation that a portion of oligodendrocytes are derived from outside the En1-area as described above. Furthermore, we found that these immigrant Sox9 + oligodendrocytes were much more proliferative than not only the ventral r1-derived Sox9 − oligodendrocytes in the Sox9 cKO mice but also the control OPCs (Fig. 8D) . It is possible that the Sox9-positive cells are attempting to compensate for the reduced number of oligodendrocytes produced within the En1-area. Further investigation will be, however, needed to elucidate the possible molecular mechanism underlying the control of oligodendrocytic cell number in this region.
In this study, we also revealed that the Sox9 gene is involved in multiple oligodendrocyte developmental processes in the cerebellum in a gene dosage-dependent manner. At early stages of oligodendrocytogenesis, generation of OPCs from the Olig2 NE domain was delayed by 1 day in heterozygotes (En1-Cre:Sox9 flox/+ ) and by 2 days in homozygotes (En1-Cre:Sox9 flox/flox ), suggesting that Sox9 participates in regulating the timing of OPC generation. At early and mid-oligodendrocytogenesis stages, we observed a transient increase in the number of oligodendrocyte lineage cells in the ventral r1 of the heterozygous mice (En1-Cre:Sox9 flox/+ ). Our cell cycle remaining/exit assays revealed that cell cycle exit of OPCs was delayed in the heterozygotes, which led to an increase in proliferating OPCs. This suggests that two copies of Sox9 are required for proper regulation of the cell cycle exit of OPCs. On the other hand, the number of oligodendrocyte lineage cells was greatly reduced in the homozygotes at early and mid-oligodendrocytogenesis stages. We observed a significant increase in cell apoptosis in homozygotes but not in the heterozygotes, which may account for the reduction of OPCs in the homozygotes. This indicates that a single copy of Sox9 is required for survival of OPCs. Similar results were obtained in our in vitro studies. Maturation of oligodendrocytes was impaired in the cerebellum in the Sox9 mutants in a gene dosage-dependent manner, from a morphological as well as gene expression vantage point. Abnormal immature morphology of mutant oligodendrocytes was also confirmed by electron microscopy. These findings suggest that Sox9 is involved in maturation of oligodendrocytes in a gene dosage-dependent manner.
In the spinal cord, gene depletion of Sox9 does not severely disturb the development of oligodendrocytes (Stolt et al., 2003) . However, double knockout of Sox9 and Sox10 results in severe impairment of oligodendrocyte development in the spinal cord, resembling the phenotype in the cerebellum of Sox9-deficient animals (Finzsch et al., 2008) . This suggests that Sox9 and Sox10 redundantly participate in oligodendrocyte development in the spinal cord, while Sox9 is essential for development of oligodendrocytes produced within the En1-area.
In this study, we investigated the origins of oligodendrocytes in the cerebellum. Furthermore, we clarified the relevance of Sox9 in the oligodendrocyte development in this region. Our findings aim to contribute to the design of new strategies aimed at therapy for demyelinating lesions caused by multiple sclerosis, brain injury, inflammation, and other disease conditions.
